CAJ | 학술논문

目的探讨老年冠心病患者使用低分子肝素的安全性。方法观察24例老年冠心病成功进行PTCA术后及51例对照组使用低分子肝素(速避凝)10000ICUAXa，每日2次共10d后出血情况及凝血机制改变。结果用药后两组出血情况、其它脏器合并症及凝血时间测定等均无明显差异，老年组血浆纤维蛋白原(FBI)较对照组明显增高(4.69±1.36，3.95±1.01，P＜0.05)，对照组治疗后FBI较治疗前明显降低(3.95±1.01，3.33±0.41，P＜0.05)。结论老年人应用较大剂量低分子肝素具有相对好的安全性。
목적 탐토노년관심병환자사용저분자간소적안전성。방법 관찰24례노년관심병성공진행PTCA술후급51례대조조사용저분자간소(속피응)10000ICUAXa，매일2차공10d후출혈정황급응혈궤제개변。결과 용약후량조출혈정황、기타장기합병증급응혈시간측정등균무명현차이，노년조혈장섬유단백원(FBI)교대조조명현증고(4.69±1.36，3.95±1.01，P＜0.05)，대조조치료후FBI교치료전명현강저(3.95±1.01，3.33±0.41，P＜0.05)。결론 노년인응용교대제량저분자간소구유상대호적안전성。
Objective In order to find the security of low molecular weightheparin used in elderly patients with coronary heart diseas e(CHD).Methods We observed the bleeding and blood coagubility(PL T,PT and APTT) in 24 elderly patients with CHD who were performed percutaneous t ransluminal coronary angioplasty and 51 young man controls with CHD,after hypode rm ical injection of low molecular weight heparin 10 000 ICUAXa twice a day for 10 days.Results There was no significant difference between t he e lderly and the controls in bleeding,complication.PLT,PT and APTT.FIB was higher in the elderly patients than in the young controls(4.69±1.36 vs 3.95±1.01 ，P＜0.05).FIB decreased apparently(3.95±1.01 vs 3.33±0.41，P＜0 .05)in the young controls after treatment.Conclusions These data suggest that elderly patients may have more serious coagulation.It is secure that elderly patients use low molecular weight heparin.